Research suggests that each 10-kilogram reduction in body weight typically decreases total cholesterol by approximately 5-8 mg/dL and LDL cholesterol by 5-7 mg/dL
In Q1 2025, 24% of patients with both diabetes/obesity and OSA initiated a GLP-1 therapy within six months of diagnosis, compared to 18% of patients with diabetes/obesity alone
Storage: Prior to reconstitution, store vials in a controlled environment at -20C for long-term stability
The abdominal area also provides a large surface area for site rotation, which becomes important for long-term therapy
Additionally, GLP-1 injections enhance insulin secretion in response to food, allowing the body to process glucose more efficiently, while also reducing glucagon release, a hormone that can raise blood sugar
RAMPs regulate signalling bias and internalisation of the GIPR